Success Metrics

Active Trials
6(86%)

Phase Distribution

Ph phase_2
1
14%
Ph phase_3
2
29%
Ph early_phase_1
1
14%
Ph phase_1
3
43%

Phase Distribution

4

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
2(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

6

trials recruiting

Total Trials

7

all time

Status Distribution
Active(6)
Terminated(1)

Detailed Status

Recruiting5
Active, not recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
6
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (14.3%)
Phase 13 (42.9%)
Phase 21 (14.3%)
Phase 32 (28.6%)

Trials by Status

active_not_recruiting114%
recruiting571%
withdrawn114%

Recent Activity

6 active trials
Showing 5 of 7
recruitingphase_3

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803
recruitingphase_1

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

NCT07446855
recruitingphase_2

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

NCT06769126
active_not_recruitingphase_1

Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib

NCT06899061
recruitingearly_phase_1

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

NCT04005690
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06952803Phase 3

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Recruiting
NCT07446855Phase 1

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

Recruiting
NCT06769126Phase 2

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Recruiting
NCT06899061Phase 1

Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib

Active Not Recruiting
NCT04005690Early Phase 1

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Recruiting
NCT07060365Phase 1

A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer

Withdrawn
NCT06120491Phase 3

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

Recruiting

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7